Applied Therapeutics — Investor Presentation (March 2024)
43 slides from Applied Therapeutics's investor presentation, Mar 11, 2024
Slide 1: Applied Therapeutics March 2024
Applied Therapeutics March 2024
Slide 2: Forward-looking statements
Various statements in this presentation concerning the Company’s future expectations, plans and prospects constitute forward-looking statements. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential
Slide 3: Applying Science to Transform Lives
3 Applying Science to Transform Lives Our mission is to create transformative, life-changing treatments for patients who desperately need them Targeting pathways with known roles in pathogenesis Novel compounds with improved potency/selectivity SCIENCE Clinical efficacy confirmed via biomarkers Purs
Slide 4: Innovative Pipeline with Near-Term Milestones
Innovative Pipeline with Near-Term Milestones 4 Compound Preclinical Phase 1 Phase 2 Phase 3 AT-007 (govorestat) AT-001 AT-003 QD Oral CNS Pediatric Ph 3 outcomes trial completed; MAA validated Q4 2023 & NDA accepted Q1 2024; PDUFA date Aug 2024 QD Oral CNS Positive pilot study data; Phase 3 12- mon
Slide 5: Aldose Reductase: An Enzyme Implicated in Multiple Metabolic Diseases
ALDOSE REDUCTASE First and rate limiting enzyme in the polyol pathway – an alternative metabolic pathway activated under stress Converts sugar to reduced sugar alcohols, which are toxic Prior attempts to inhibit Aldose Reductase were hindered by lack of selectivity and off-target tox issues 5 Aldose
Slide 6: Govorestat (AT-007) Galactosemia
Govorestat (AT-007) GALACTOSEMIA Positive adult & pediatric biomarker data Pediatric Ph 3 clinical outcomes study completed Regulatory submissions under review (MAA validated; NDA accepted) • Orphan Drug Designation • Pediatric Rare Disease Designation (PRV) • Fast-Track Designation
Slide 7: Galactosemia is a Rare Metabolic Disease With No Approved Therapies
Galactosemia is a Rare Metabolic Disease With No Approved Therapies and Significant Unmet Need Disease Overview • Rare autosomal recessive metabolic disease caused by deficiencies in the GALT or GALK enzymes • Patients are unable to metabolize the simple sugar galactose, which is found in foods but
Slide 8: Govorestat Has Demonstrated Effectiveness in vitro, in vivo, and in Clinical Trials
8 in vitro Pediatric Phase 1-2 Pediatric Phase 3 • Aldose Reductase inhibition: 1,000X greater potency • Selectivity: no off-target aldehyde reductase inhibition Animal Model • Prevents CNS complications (learning/ cognition) and cataracts in a rat model of Classic Galactosemia • Decreases toxic gal
Slide 9: Deficiency in GALT or GALK Leads to Inability to Metabolize Galactose
Deficiency in GALT or GALK Leads to Inability to Metabolize Galactose; AR Converts Excess Galactose to Toxic Galactitol Energy Production GALK GALT NORMAL METABOLISM Classic Galactosemia GALK Deficiency ALDOSE REDUCTASE galactitol toxic accumulation of galactitol galactitol no natural enzyme to meta
Slide 10: Natural History: Galactosemia is a Progressive Disease
10 Natural History: Galactosemia is a Progressive Disease that Worsens with Age; Disease Severity Correlates with Plasma Galactitol Level Speech Cognition Behavior Motor Skills Abstract eP011: Progressive Worsening of Central Nervous System Phenotype in Children with Classic Galactosemia: a Cross-Se
Slide 11: Govorestat is a Selective, CNS Penetrant Aldose Reductase Inhibitor
Energy Production GALK GALT Classic Galactosemia GALK Deficiency ALDOSE REDUCTASE galactose Gal-1p Glucose-1-P Govorestat (AT-007) is a Selective, CNS Penetrant Aldose Reductase Inhibitor Blocks production of the toxic metabolite galactitol Phytila et al. JIMD Rep. 2015; 15: 79–93.; Burgard et al. R
Slide 12: Govorestat Reduced Galactitol in Adult Phase 1/2 Study
Govorestat Significantly Reduced Galactitol Levels in the Galactosemia Adult Phase 1/2 Study (ACTION-Galactosemia); Safe and Well-Tolerated Single Ascending Dose (n=40) Multiple Ascending Dose (n=40, 7 days) 5 mg/kg single dose 5 mg/kg 27 Days Daily Dosing (n=4) Adult Galactosemia Patients Healthy V
Slide 13: ACTION-Galactosemia Kids Pediatric Registrational Study Design
13 ACTION-Galactosemia Kids Pediatric Registrational Clinical Study Design (47 Children Age 2-17) Govorestat Dose Escalation Biomarker Assessment of Galactitol Placebo cross to active in 18 month open-label extension PK/PD Dose Range Finding & Biomarker Data Long-Term Clinical Outcomes Placebo Scree
Slide 14: Govorestat Reduced Plasma Galactitol by 40%
Govorestat Treatment Reduced Plasma Galactitol Levels by 40% (p<0.001 vs. placebo); Improvement in Galactitol Biomarker Provided Clinical Benefit Across Activities of Daily Living, Behavior, Cognition, Adaptive Skills and Tremor 14 Weight Group AT-007 Dose (QD) % Reduction From Baseline >40kg 15mg/k
Slide 15: Govorestat Positively Impacted Behavior, Daily Living Skills, Cognition and Tremor
Govorestat Treatment Positively Impacted Behavior, Daily Living Skills, Adaptive Skills, Cognition, Fine Motor Skills & Tremor Clinical outcomes declined in the placebo group, while govorostat treated patients stabilized or improved over 18 months 15 Behavioral Symptoms Index Social Skills Withdrawa
Slide 16: Caregiver Exit Interviews Support Clinical Meaningfulness
Caregiver Exit Interviews Support the Clinical Meaningfulness of Govorestat Treatment Caregivers noted an improvement or stabilization of disease on all categories of symptoms in the govorestat treated group vs. placebo.* 0% 20% 40% 60% 80% 100% govorestat placebo % Change Behavior (Emotional) impro
Slide 17: Galactitol Reduction Correlated with Clinical Outcomes Benefit
Galactitol Reduction Correlated with Clinical Outcomes Benefit Galactitol level at 3 months statistically correlated with change in clinical outcomes at 18 months CFB= Change From Baseline; correlation plots include data for all subjects who completed the same BASC test at baseline and 18 months (e.
Slide 18: Safety Summary
Safety Summary 18 • Govorestat was safe and well-tolerated with no serious adverse events • All adverse events were mild to moderate • Adverse events & lab values were balanced between govorestat and placebo groups Placebo (N=16) Number (%) of Subjects Govorestat (N=31) Number (%) of Subjects Subjec
Slide 19: Strong Demand for Galactosemia Education and Treatment
Strong Demand for Galactosemia Education and Treatment from Caregivers and HCPs 19 Awards Engaging the Galactosemia Community through Social 35,000+ post views 537 Facebook followers Support and Education at Galactosemia.com 100,000+ website visitors Sharing the Galactosemia Story via 2D & 3D MOD Vi
Slide 20: Govorestat (AT-007) SORD Deficiency
Govorestat (AT-007) SORD DEFICIENCY Preclinical proof of concept demonstrated Positive pilot study completed Registrational Phase 3 study positive interim 12-month data • Orphan Drug Designation
Slide 21: SORD Deficiency is a Rare Neurological Disease With No Approved Therapies
SORD Deficiency is a Rare Neurological Disease with No Approved Therapies and High Unmet Need Disease Overview • Sorbitol Dehydrogenase Deficiency (SORD Deficiency) is a progressive, debilitating hereditary neuropathy that affects peripheral nerves and motor neurons, resulting in significant disabil
Slide 22: Govorestat Effective in vitro, in vivo, and in SORD Pilot Study
22 in vitro Pilot Study Phase 3 • Aldose Reductase inhibition: 1,000X greater potency • Selectivity: no off-target aldehyde reductase inhibition Animal Model • Prevents oxidative stress, neuronal degeneration and mobility phenotype in drosophila SORD model • Safe and well tolerated in healthy volunt
Slide 23: Aldose Reductase Inhibition Addresses the Underlying Cause of SORD Neuropathy
23 Aldose Reductase Inhibition Addresses the Underlying Cause of SORD Neuropathy by Preventing Conversion of Glucose to Sorbitol sorbitol Hexokinase Pathway ALDOSE REDUCTASE Energy polyol pathway AT-007 • People with SORD Deficiency are missing the SORD enzyme, which follows Aldose Reductase in the
Slide 24: Govorestat Reduces Sorbitol in SORD Patient Cells; Drosophila Model
24 Govorestat Treatment Reduces Sorbitol Levels in SORD Patient Cells; Prevents CNS Phenotype in a Drosophila SORD Deficiency Model • Sorbitol accumulation causes mitochondrial dysfunction and reactive oxygen species formation, resulting in axonal neuropathy • Treatment with govorestat (AT-007) redu
Slide 25: AT-007 Reduced Sorbitol in 30-Day Open-Label Pilot Trial
AT-007 Significantly Reduced Sorbitol in Patients with SORD Deficiency in 30-Day Open-Label Pilot Trial 25 Mean baseline sorbitol level was ~38,000ng/ml Pilot open-label study data in 8 SORD patients demonstrated 66% mean reduction in sorbitol (range 54%-75%) sorbitol (ng/ml) 0 5,000 10,000 15,000 2
Slide 26: SORD Neuropathy Phase 3 Registrational Study (INSPIRE)
SORD Neuropathy Phase 3 Registrational Study (INSPIRE) Double-Blind, Randomized, Placebo-Controlled Multi-Center Study in ~50 SORD Patients >16 years old Primary Biomarker Efficacy: Reduction in sorbitol vs. baseline at 3 months Exploratory Biomarker: NFL reduction at 3 months CMT-FOM lower limb dom
Slide 27: Govorestat Reduced Sorbitol in the Phase 3 INSPIRE Trial
Govorestat Significantly Reduced Sorbitol Levels in the Ph 3 INSPIRE Trial 3 Month Sorbitol Reduction Interim Analysis 27 Mean baseline sorbitol level was ~29,000ng/ml Govorestat (AT-007): 52% Reduction in Sorbitol from Baseline (~16,000ng/ml) p<0.001 vs. placebo sorbitol reduction (ng/ml) Placebo A
Slide 28: INSPIRE Trial 12 Month Interim Data Overview
INSPIRE Trial 12 Month Interim Data Overview 28 Co-primary endpoints at 12 month analysis: • Primary clinical efficacy endpoint: Statistically significant correlation between sorbitol levels and change in clinical outcomes at 12 months of treatment on combined measures of the CMT Functional Outcome
Slide 29: Statistically Significant Improvement in CMT-Health Index Scores
29 Govorestat Treated Patients Demonstrated a Statistically Significant Improvement in CMT-Health Index (CMT-HI) Scores at 12 Months (p=0.01 vs. placebo) Lower score (negative change from baseline) represents improvement in disease symptoms; measures with “8” were statistically significant vs. place
Slide 30: Trend Towards Improvement in 10MWR, Dorsiflexion and 6 Minute Walk
30 Govorestat Treated Patients Demonstrated Trend Towards Improvement in 10MWR, Dorsiflexion and 6 Minute Walk at 12 Months For foot Dorsiflexion, the estimate and the CI were divided by 10 in order to present within the x−axis range (actual values are 10X the values on the slide); For 6-minute walk
Slide 31: Patient Disposition & Safety
31 Placebo N=18 n (%) Govorestat N=38 n (%) Combined N=56 n (%) Randomized 18 (100.0%) 38 (100.0%) 56 ( 100.0%) Ongoing 17 ( 94.4%) 34 ( 89.5%) 51 ( 91.1%) Discontinued 1 (5.6%) 4 (10.5%) 5 (8.9%) Reason for Discontinuation: Adverse Event 0 ( 0.0%) 3 (7.9%) 3 (5.4%) Reason for Discontinuation: Withd
Slide 32: Inherited Neuropathy Consortium Centers of Excellence and Global CMT Registries
32 Inherited Neuropathy Consortium Centers of Excellence and Global CMT Registries Exist to Support Diagnosis and Treatment University of Pennsylvania School of Medicine Children’s Hospital of Philadelphia Centers participating in INSPIRE Phase 2/3 trial www.rarediseasesnetwork.org/cms/inc/centers#C
Slide 33: Aldose Reductase Inhibition Improves PMM2 Activity
33 Aldose Reductase Inhibition Improves PMM2 Activity Govorestart Granted Orphan & Pediatric Rare Disease Designation for PMM2-CDG; Single-Patient IND Open – Phase 2 Ready sorbitol glucose Normal Metabolism ALDOSE REDUCTASE Protein Glycosylation polyol pathway activation Govorestat • AR inhibition b
Slide 34: AT-001 Diabetic Cardiomyopathy
AT-001 DIABETIC CARDIOMYOPATHY Phase 1/2 pilot study completed Phase 3 study completed
Slide 35: Diabetic Cardiomyopathy is a Form of Heart Failure Affecting ~20% of Diabetics
Diabetic Cardiomyopathy (DbCM) is a Form of Heart Failure Affecting ~20% of Diabetics; Significant Unmet Need with No Approved Treatments Disease Overview • Form of Heart Failure (Stage B) causing structural cardiac damage and resulting in decreased cardiac functional capacity • Affects ~20% of diab
Slide 36: Diabetic Cardiomyopathy: Mechanism of Disease
Aldose Reductase, the first and rate limiting enzyme in the polyol pathway, converts this glucose into sorbitol and eventually fructose Both Type 1 and Type 2 diabetes results in hyperglycemia; the polyol pathway is then hyperactivated to rid the body of the excess glucose Excess sorbitol and fructo
Slide 37: AT-001 Has Demonstrated Effectiveness in vitro, in vivo, and in Phase 1/2 Trials
37 in vitro Cell Culture Phase 1/2 Phase 3 Study • Aldose Reductase inhibition: 1,000X greater potency • Selectivity: no off-target aldehyde reductase inhibition Prevents ROS formation, mitochondrial dysfunction and senescence in cells in culture Animal Model Improves cardiac energetics and prevents
Slide 38: AT-001 Provides Greater Potency and Improved Target Selectivity
38 Poster # 632: “Addressing safety and specificity with aldose reductase inhibition: development of AT-001 for diabetic cardiomyopathy” 56th Annual Meeting of the European Association for the Study of Diabetes (EASD) Sept 2020 In Vitro: AT-001 Provides Greater Potency and Improved Target Selectivit
Slide 39: AT-001 Treatment Prevents Reactive Oxygen Species Formation
Dihydroethidium(DHE) staining for cytosolic reactive oxygen species HG HG + AT001 DHE HG- NHK cells exposed to 25mM glucose for 48hrs HG + AT001 - cells treated with 0.18nM AT001 along with above mentioned HG exposure Cytosolic reactive oxygen species attenuated by AT 001 in skin cells treated with
Slide 40: AT-001 Improves Cardiac Energetics in an Animal Model of DbCM
40 0 5 10 15 20 0 20 40 60 80 100 120 140 vehicle AT-001 METHODS & EXPERIMENTAL DESIGN 60% High-Fat Diet Week Mouse euthanized & heart extracted for isolated working heart perfusion Echo Echo AT-001 (20 mg/kg daily) C57BL/6J hAR-Tg 8 weeks old Streptozotocin (75 mg/kg) hAR-Tg: human Aldose Reductase
Slide 41: DbCM Phase 3 Study (ARISE-HF) Design
DbCM Phase 3 Study (ARISE-HF) Design Randomized, Placebo-Controlled Study in DbCM Patients at High Risk of Progression Efficacy (15 Months) Primary Endpoint: Cardiac Functional Capacity (as measured by Peak VO2 change from baseline) Prespecified subgroup analysis of patients not on SGLT2 or GLP1 Sec
Slide 42: DbCM Phase 3 Topline Results
DbCM Phase 3 Topline Results Positive Effect of AT-001 on Cardiac Functional Capacity; Statistically Significant in Patients not on SGLT2/GLP1 PHASE 3 Placebo (N=230) AT-001 1000mg (N=228) AT-001 1500mg (N=231) Serious Adverse Events (SAEs) 33 (14%) 28 (12%) 40 (17%) Treatment-Emergent Adverse Event
Slide 43: Applying Science to Transform Lives
43 Applying Science to Transform Lives Our mission is to create transformative, life-changing treatments for patients who desperately need them Targeting pathways with known roles in pathogenesis Novel compounds with improved potency/selectivity SCIENCE Clinical efficacy confirmed via biomarkers Pur
Applied Therapeutics — Investor Presentation (March 2024) on 6ix